A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Soquelitinib (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell leukaemia; T-cell lymphoma
- Focus Adverse reactions; First in man
- Sponsors Corvus Pharmaceuticals
Most Recent Events
- 20 Mar 2025 According to a Corvus Pharmaceuticals media release, data from this trial presented at the 16th Annual T-Cell Lymphoma Forum
- 20 Mar 2025 Results presented in the Corvus Pharmaceuticals Media Release
- 19 Feb 2024 Status changed from recruiting to active, no longer recruiting.